Alvotech (ALVO) P/E Ratio History
UndervaluedTrading at 36.8x vs 5Y avg 522.1x · 25th percentile · Below historical baseline · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Alvotech (ALVO) trades at a price-to-earnings ratio of 36.8x, with a stock price of $3.68 and trailing twelve-month earnings per share of $-0.24.
The current P/E is 93% below its 5-year average of 522.1x. Over the past five years, ALVO's P/E has ranged from a low of 28.5x to a high of 1973.1x, placing the current valuation at the 25th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, ALVO trades at a 60% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, ALVO commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ALVO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ALVO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ALVO P/E vs Peers
Biosimilar developers and manufacturers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $193B | 25.2 | 8.56 | +88% | |
| $39B | 27.7 | - | +183%Best | |
| $444B | 106.1 | - | -1% | |
| $613B | 23.1 | 1.55 | +91% | |
| $138B | 17.9 | - | -4% | |
| $32B | 24.5 | - | -21% | |
| $66B | 15.3Lowest | 2.41 | +8% | |
| $317B | 17.6 | 0.83Best | +8% | |
| $92B | 19.9 | - | +49% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ALVO Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $5.13 | $0.00 | 1973.1x | +278% |
| FY2025 Q3 | - | $8.19 | $0.21 | 38.5x | -93% |
| FY2025 Q2 | Jun 30 2025 | $9.12 | $0.19 | 48.2x | -91% |
| FY2025 Q1 | Mar 31 2025 | $9.67 | $0.34 | 28.5x | -95% |
Average P/E for displayed period: 522.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALVO — Frequently Asked Questions
Quick answers to the most common questions about buying ALVO stock.
What is ALVO's P/E ratio?
Alvotech (ALVO) trailing twelve-month P/E ratio is 36.8x, based on TTM diluted EPS of $-0.24. The 5-year average P/E is 522.1x and the historical range spans 28.5x to 1973.1x.
Is ALVO stock overvalued or undervalued?
ALVO trades at 36.8x P/E, below its 5-year average of 522.1x. At the 25th percentile of its historical range (28.5x–1973.1x), the stock is priced at a discount to its own history.
Is ALVO stock expensive?
No, ALVO is not expensive on a historical basis. The current P/E of 36.8x is below the 5-year average of 522.1x and sits at the 25th percentile of its valuation range.
What is ALVO's historical P/E range?
Over the past 5 years, ALVO's P/E ratio has ranged from 28.5x to 1973.1x, with a median of 48.2x and an average of 522.1x. The current P/E of 36.8x places the stock at the 25th percentile of this range. Full historical data spans 2025–2025.
How does ALVO's P/E compare to the S&P 500?
ALVO trades at 36.8x P/E versus the S&P 500 median of 25.3x. The 45% premium to the market typically reflects higher expected earnings growth or quality.
How does ALVO's valuation compare to Healthcare peers?
Alvotech P/E of 36.8x compares to the Healthcare sector median of 23.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ALVO's PEG ratio?
ALVO PEG ratio is N/A, based on a P/E of 36.8x and EPS growth of 111.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ALVO's earnings yield?
ALVO earnings yield is 2.72%, the inverse of its 36.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.